Literature DB >> 10399028

Somatostatin receptors present knowledge and future directions.

A Schonbrunn1.   

Abstract

Genes for five somatostatin receptor subtypes, designated sst1-5, have been cloned and shown to belong to the seven transmembrane domain receptor family. The sst2 mRNA transcript is alternatively spliced to generate two related receptor products (sst2A and sst2B) which differ in their carboxylterminal sequence whereas each of the other genes is transcribed to give a single unique receptor protein. The six sst receptor subtypes all bind SRIF14, SRIF28 and the cortistatins with high affinity but vary in their affinity for analogs, such as octreotide. Although the tissue distribution of sst mRNAs has been extensively examined, much less is known about the cellular distribution of the individual receptor proteins. Recent studies with sst subtype specific antibodies have localized individual sst receptors to specific cell types within the rat gastrointestinal tract, pancreas, pituitary and brain. Furthermore, sst receptors have recently been identified in human tumors by immunocytochemistry, providing a significantly improved method for sst receptor detection. All six sst receptor subtypes are linked to guanine nucleotide binding proteins (G proteins) and lead to inhibition of adenylyl cyclase following hormone binding. The sst receptors also regulate a variety of different effectors via G proteins, including calcium and potassium channels and serine and tyrosine phosphatases. In addition to signalling, two other processes are activated by hormone binding: receptor desensitization and receptor internalization. The extent to which these occur seems to vary for the different receptor subtypes. Recent studies have shown that the sst2A receptor is rapidly phosphorylated upon hormone binding, suggesting that this phosphorylation may be responsible for the desensitization and/or internalization of this receptor. The importance of receptor regulation in cellular responsiveness to somatostatin and for receptor detection as well as the molecular mechanisms by which these processes occur provide important areas for future investigations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10399028     DOI: 10.1093/annonc/10.suppl_2.s17

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  14 in total

1.  What can gallium-68 PET add to receptor and molecular imaging?

Authors:  Adil Al-Nahhas; Zarni Win; Teresa Szyszko; Aviral Singh; Sameer Khan; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12       Impact factor: 9.236

2.  Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line.

Authors:  Valeria Cambiaghi; Eleonora Vitali; Diego Morone; Erika Peverelli; Anna Spada; Giovanna Mantovani; Andrea Gerardo Lania
Journal:  Endocrine       Date:  2016-07-12       Impact factor: 3.633

Review 3.  (68)Ga-labeled radiopharmaceuticals for positron emission tomography.

Authors:  Dinesh Shetty; Yun-Sang Lee; Jae Min Jeong
Journal:  Nucl Med Mol Imaging       Date:  2010-10-12

Review 4.  Modern management of cancer-related intestinal obstruction.

Authors:  M P Davis; C Nouneh
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

5.  Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies.

Authors:  H Kulaksiz; R Eissele; D Rössler; S Schulz; V Höllt; Y Cetin; R Arnold
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

6.  Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas.

Authors:  Elaine Lu Wang; Zhi Rong Qian; Shozo Yamada; Md Mustafizur Rahman; Naoko Inosita; Teruyoshi Kageji; Hideko Endo; Eiji Kudo; Toshiaki Sano
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

Review 7.  Clinical applications of Gallium-68.

Authors:  Sangeeta Ray Banerjee; Martin G Pomper
Journal:  Appl Radiat Isot       Date:  2013-02-20       Impact factor: 1.513

8.  Update on management of midgut neuroendocrine tumors.

Authors:  Amir Mehrvarz Sarshekeh; Daniel M Halperin; Arvind Dasari
Journal:  Int J Endocr Oncol       Date:  2016-04-08

9.  Efficacy of long-term lanreotide treatment in patients with acromegaly.

Authors:  Yoel Toledano; Liat Rot; Yona Greenman; Sophia Orlovsky; Yulia Pauker; David Olchovsky; Achia Eliash; Orit Bardicef; Ofa Makhoul; Gloria Tsvetov; Michal Gershinsky; Odile Cohen-Ouaqnine; Rosane Ness-Abramof; Zaina Adnan; Jacob Ilany; Hadassah Guttmann; Mazal Sapir; Carlos Benbassat; Ilan Shimon
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

10.  Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.

Authors:  Robert D Murray; Kiwon Kim; Song-Guang Ren; Marjorie Chelly; Yutaka Umehara; Shlomo Melmed
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.